Artwork

Contenuto fornito da Jacqueline Stone and Oncololgy News Central. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Jacqueline Stone and Oncololgy News Central o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

What 3 Big Trials Mean for Breast Cancer Practice

12:48
 
Condividi
 

Manage episode 447293269 series 3560609
Contenuto fornito da Jacqueline Stone and Oncololgy News Central. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Jacqueline Stone and Oncololgy News Central o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from three key studies. Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, explains how findings from the KEYNOTE-756, monarchE, and NATALEE clinical trials are influencing decision-making for these patients. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss the evolving role of immunotherapy and how to choose between CDK4/6 inhibitors, given the recent U.S. Food and Drug Administration approval of adjuvant ribociclib for patients with early breast cancer who are at high risk for recurrence. Dr. Cobain acknowledges that these and other findings have led to “challenging discussions,” even if those conversations are ultimately beneficial.

Dr. Cobain reported various financial relationships.

Dr. Figlin reported various financial relationships.

  continue reading

130 episodi

Artwork
iconCondividi
 
Manage episode 447293269 series 3560609
Contenuto fornito da Jacqueline Stone and Oncololgy News Central. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Jacqueline Stone and Oncololgy News Central o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from three key studies. Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, explains how findings from the KEYNOTE-756, monarchE, and NATALEE clinical trials are influencing decision-making for these patients. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss the evolving role of immunotherapy and how to choose between CDK4/6 inhibitors, given the recent U.S. Food and Drug Administration approval of adjuvant ribociclib for patients with early breast cancer who are at high risk for recurrence. Dr. Cobain acknowledges that these and other findings have led to “challenging discussions,” even if those conversations are ultimately beneficial.

Dr. Cobain reported various financial relationships.

Dr. Figlin reported various financial relationships.

  continue reading

130 episodi

Alle afleveringen

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida

Ascolta questo spettacolo mentre esplori
Riproduci